Haas T, Dongradi G, Villeboeuf F, de Viel E, Verrier J, Hillion D
Artif Organs. 1985 May;9(2):164-8. doi: 10.1111/j.1525-1594.1985.tb04368.x.
In 12 chronic hemodialysis patients, postdilutional hemofiltration (HF) was substituted for conventional acetate hemodialysis (HD) (4-5 h/session with high-area capillary dialyzers). In HF, the purposes were to obtain (a) no increase in pre-HF uremia compared with pre-HD uremia (high ultrafiltrate volume), (b) an HF duration shorter than that of HD (mean ultrafiltrate rate greater than 120 ml/min), (c) a disposable cost of an HF session identical to that of an HD session (reuse of hemofilters and extemporaneous preparation of substitution fluid). One-year results were (a) an ultrafiltrate volume of 26.8 L/session and a pre-HF uremia of 35.4 mmol/L (pre-HD uremia 34.0 mmol/L), (b) a mean ultrafiltrate rate of 143 ml/min and a mean HF duration of 190 min (mean HD session duration 250 min), and (c) better clinical tolerance and vascular stability in HF than in HD (weight loss 3.5 kg in HF and 3.0 kg in HD). Reuse of filters and extemporaneous preparation of substitution fluid were not responsible for any pyrogen reaction or bacterial contamination. In conclusion, (a) compared with conventional HD, high-flux HF results included identical removal of small molecules, improvement in vascular stability, decrease in session duration, and identical disposable cost; (b) routine high-flux HF is workable in a dialysis unit; (c) vascular access is the most important limiting factor to high-flux HF. Today 30-40% of patients can be treated with this method.
在12例慢性血液透析患者中,采用后稀释血液滤过(HF)替代传统的醋酸盐血液透析(HD)(使用大面积毛细血管透析器,每次透析4 - 5小时)。在血液滤过中,目标是:(a)与血液透析前相比,血液滤过前的尿毒症水平不升高(超滤量高);(b)血液滤过的时间短于血液透析(平均超滤率大于120 ml/分钟);(c)一次血液滤过治疗的一次性成本与一次血液透析治疗相同(血液滤过器复用和临时配制置换液)。一年的结果如下:(a)每次治疗的超滤量为26.8 L,血液滤过前的尿毒症水平为35.4 mmol/L(血液透析前为34.0 mmol/L);(b)平均超滤率为143 ml/分钟,平均血液滤过时间为190分钟(血液透析平均治疗时间为250分钟);(c)与血液透析相比,血液滤过的临床耐受性和血管稳定性更好(血液滤过体重减轻3.5 kg,血液透析体重减轻3.0 kg)。滤器复用和临时配制置换液未引起任何热原反应或细菌污染。总之,(a)与传统血液透析相比,高通量血液滤过的结果包括小分子清除相同、血管稳定性改善、治疗时间缩短以及一次性成本相同;(b)常规高通量血液滤过在透析单元可行;(c)血管通路是高通量血液滤过最重要的限制因素。如今,30% - 40%的患者可以用这种方法治疗。